Alzheimer's drug shows promise in imaging study

02/28/2010 | Reuters

Bapineuzumab, an experimental drug being developed by Pfizer, Elan and Johnson & Johnson, appeared to reduce beta amyloid buildup in the brain by about 25% in Alzheimer's disease patients, according to a study. Researchers used carbon-11-labeled Pittsburgh compound B, an imaging agent that binds with clogged areas of the brain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD